Zhejiang Jolly Pharmaceutical Co.,Ltd. (300181.SZ) has announced that it has received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA). The approval allows the company's already marketed product, Lianlianhua Granules, to proceed with clinical research for new therapeutic indications.

According to the review, the clinical trial application for Lianlianhua Granules, submitted on June 1, 2026, meets the relevant requirements for drug registration. Upon further refinement of the clinical trial plan, the NMPA has granted approval for conducting the trial aimed at treating perimenopausal syndrome associated with anxiety in the context of heart-kidney imbalance syndrome.

Following the receipt of this clinical trial approval notice, the company will organize and conduct the clinical trials in accordance with relevant national drug registration regulations. Due to the specific nature of drug development, the process from clinical trials to marketing approval is lengthy, involves multiple stages, and carries high risks, making it susceptible to various uncertain factors. Therefore, the approval of this clinical trial is not expected to have a significant impact on the company's performance.